Trial reportEuropean journal of clinical pharmacology2013
Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study.
Trial report in European journal of clinical pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Effectiveness of eradication therapy for Helicobacter pylori infection in Africa: a systematic review and meta-analysis.BMC gastroenterology · 2023Pooled it
- Sequential versus standard triple first-line therapy for Helicobacter pylori eradication.The Cochrane database of systematic reviews · 2016Pooled it
- Meta-analysis: is combination of tetracycline and amoxicillin suitable for Helicobacter pylori infection?World journal of gastroenterology · 2015Pooled it
- Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy.BMJ (Clinical research ed.) · 2013Pooled it
- Optimized sequential therapyWorld journal of gastroenterology · 2024Trial
- Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial.European journal of clinical pharmacology · 2019Trial
- Sequential versus Standard Triple Therapy for First-LineAntibiotics (Basel, Switzerland) · 2024Review
- Article
- Infections withWorld journal of gastroenterology · 2019Review
- Current Paradigm and Future Directions for Treatment of Helicobacter pylori Infection.Current treatment options in gastroenterology · 2014Article
- Gastroretentive drug delivery systems for the treatment of Helicobacter pylori.World journal of gastroenterology · 2014Review
- Sequential therapy versus standard triple therapy in Helicobacter pylori eradication in a high clarithromycin resistance setting.International journal of clinical and experimental medicine · 2014Article
- Quinolone-containing therapies in the eradication of Helicobacter pylori.BioMed research international · 2014Review
- How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography?World journal of gastroenterology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEradication rates following standard triple therapy for Helicobacter pylori infection are declining. Recent studies, conducted in a number of countries, have shown that sequential therapy for H. pylori infection yields high cure rates.
aimTo compare the efficacy and tolerability of a sequential regimen as a first-line treatment of H. pylori infection with a standard triple treatment regime in Morocco.
methodsA total of 281 naive H. pylori-infected patients, confirmed by histological examination, were assigned randomly to one of two treatment groups: standard triple therapy [omeprazole (20 mg bid) + amoxicillin (1 g bid) + clarithromycin (500 mg bid) for 7 days] or sequential therapy [omeprazole (20 mg bid) + amoxicillin (1 g bid) for 5 days, followed by omeprazole (20 mg bid) + tinidazole (500 mg bid) + clarithromycin (500 mg bid) for an additional 5 days]. H. pylori eradication was checked 4-6 weeks after treatment initiation by using a ¹³C-urea breath test. Compliance and adverse events were assessed.
resultsThe two groups did not differ significantly in gender, age, previous disease history, endoscopic and histological features and smoking. The intention-to-treat and per-protocol eradication rates were 65.9 and 71 % in the standard triple therapy group, and 82.8 and 89.9 % in the sequential therapy group, respectively. The eradication rate was significantly higher in the sequential therapy group than in the standard triple therapy group (p < 0.001), There was no statistically significant difference in compliance (97.5 vs. 96.3 %) and incidence of side-effects (27.5 vs. 27.9 %) between the two groups.
conclusionsBased on our results, we conclude that for eradication of H. pylori infection, the 10-day sequential therapy is more effective than the standard triple therapy and is equally tolerated. These results confirm those of other studies in other countries.
Indexed as
Identifiers
23695545What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.